Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19

Authors

• Samuel M. Rubinstein, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
• Divaya Bhutani, Herbert Irving Comprehensive Cancer Center, United States.
• Ryan C. Lynch, University of Washington, Seattle, WA, United States.
• Chih-Yuan Hsu, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
• Yu Shyr, Vanderbilt University Medical Center, Nashville,, TN, United States.
• Shailesh Advani, Georgetown University Medical Center, Washington DC, MD, United States.
• Ruben A. Mesa, Mays Cancer Center at UT Health San Antonio, San Antonio, TX, United States.
• Sanjay Mishra, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
• Daniel P. Mundt, Advocate Aurora HealthFollow
• Dimpy P. Shah, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
• R Alejandro Sica, Montefiore/Einstein Cancer Center, Bronx, NY, United States.
• Keith E. Stockerl-Goldstein, Washington University in St. Louis, St. Louis, MO, United States.
• Catherine Stratton, Yale University, New Haven, United States.
• Matthias Weiss, Advocate Aurora Health
• Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
• Melissa Accordino, Columbia University, New York, NY, United States.Follow
• Sarit E. Assouline, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada.
• Joy Awosika, University of Cincinnati Cancer Center, Cincinnati, OH, United States.Follow
• Ziad Bakouny, Brigham and Women's Hospital, Boston, MA, United States.Follow
• Babar Bashir, Thomas Jefferson University Hospital, Philadelphia, PA, United States.Follow
• Stephanie Berg, Loyola University Medical Center, Maywood, IL, United States.Follow
• Mehmet Asim Bilen, Winship Cancer Institute of Emory Univesity, Atlanta, GA, United States.Follow
• Cecilia A. Castellano, Winship Cancer Institute of Emory University, Atlanta, GA, United States.Follow
• Jacob C. Cogan, Columbia University, New York, NY, United States.
• Devendra Kc, Hartford HealthCare Cancer Institute, Hartford, CT, United States.
• Christopher R. Friese, University of Michigan-Ann Arbor, Ann Arbor, United States.
• Shilpa Gupta, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States.
• Daniel Hausrath, Vanderbilt University Medical Center, Nashville, Tennessee, United States.
• Clara Hwang, Henry Ford Cancer Institute, Detroit, MI, United States.
• Nathalie A. Johnson, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada.
• et al

Recommended Citation

Rubinstein SM, Bhutani D, Lynch RC, et al. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discov. 2022;3(3):181-193. doi:10.1158/2643-3230.BCD-22-0013

Affiliations

Aurora Cancer Care

Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anti-cancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared to control populations of patients with non-B-lymphoid hematologic malignancies. Among patients with B-lymphoid malignancies, those who received anti-cancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared to patients with B-lymphoid malignancies off therapy, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.

Type

Article

PubMed ID

35262738